ACAD vs MRK
ACADIA Pharmaceuticals Inc. vs Merck & Co. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | MRK |
|---|
| AI Score |
69
|
70
|
| Price |
$29.41
|
$130.34
|
| P/E Ratio |
13.07×
|
103.53×
|
| ROE |
31.9%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
75.4%
|
| Debt / Equity |
0.06×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
78.4
|
64.5
|
| Beta |
0.845
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus MRK.
MRK leads by 1 points.
MRK scores 70/100 (Buy) versus ACAD at 69/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical